EUVIMEDEUVIMED entdecken
Crossref

Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting

Tine Litske Bennedsen iD, Mikkel Runason Simonsen iD, Paw Jensen, Peter Brown, Pär Josefsson, Arushi Khurana, Matthew Maurer, Michael Roost Clausen iD, Andriette Dessau-Arp, Jennifer Bøgh Jørgensen, Judit Jørgensen, Thomas Stauffer Larsen und 3 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Tine Litske Bennedsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Combined Chemotherapy Protocols, Patient Selection, Eligibility Determination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Danish Cancer Society Research Center, Danish Data Science Academy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of new first‐line treatments for patients with follicular lymphoma (FL) is becoming increasingly challenging due to already excellent survival outcomes. The present study investigated the outcomes of patients with FL who underwent contemporary first‐line therapies but would not have been eligible for inclusion in recent trials and explored how commonly used in/exclusion criteria impacted their survival outcomes. This study included adult patients diagnosed with FL in the period 2000–2018 registered in the Danish Lymphoma Registry. Through searches on ClinicalTrials.gov , four recent 1st line phase 3 randomized controlled trials with R‐Bendamustine, R‐CVP, and/or R‐CHOP as control or experimental arms were included. Inclusion and exclusion criteria for each trial were retrieved and categorized. Patients were then divided into trial‐eligible and ineligible groups according to blood test results correlated to organ function and ECOG performance score (PS). Survival outcomes were significantly worse among trial‐ineligible patients, with adjusted differences between trial‐eligible and ineligible patients of 12%–20% in five‐year overall survival (OS) overall. Inclusion criteria based on PS and renal function were the main drivers of OS differences. More inclusive trials will lead to faster recruitment and secure focus on developing medicines for the group of patients with the worst outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsPatient SelectionEligibility DeterminationHumansMaleFemaleMiddle AgedAgedTreatment OutcomeAdultRegistriesVincristineAged, 80 and overCyclophosphamideRituximabDoxorubicinPrednisoneRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

clinical trialeligibility determinationfollicular lymphomaselection criteria

Substanzen

VincristineCyclophosphamideRituximabDoxorubicinPrednisone

Autor:innen und Institutionen

  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Internal Medicine Thisted, Aalborg University Hospital, Thisted, Denmark.
  • Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
  • Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Mayo Clinic Rochester - Division of Hematology, Rochester, Minnesota, USA.
  • Department of Hematology, Vejle Hospital, Vejle, Denmark.

ORCID-Profile: Tine Litske Bennedsen, Mikkel Runason Simonsen, Michael Roost Clausen, Lars Møller Pedersen

Förderung

  • Danish Cancer Society Research Center
  • Danish Data Science Academy

Zitieren

APA

Bennedsen, T. L., Simonsen, M. R., Jensen, P., Brown, P., Josefsson, P., Khurana, A., Maurer, M., Clausen, M. R., Dessau-Arp, A., Jørgensen, J. B., Jørgensen, J., Larsen, T. S., Pedersen, L. M., Jakobsen, L. H., & El-Galaly, T. C. (2025). Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal of Haematology. https://doi.org/10.1111/ejh.14373

Vancouver

Bennedsen TL, Simonsen MR, Jensen P, Brown P, Josefsson P, Khurana A, et al. Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal of Haematology. 2025. doi:10.1111/ejh.14373

BibTeX
@article{Bennedsen2025,
  author = {Bennedsen, Tine Litske and Simonsen, Mikkel Runason and Jensen, Paw and Brown, Peter and Josefsson, Pär and Khurana, Arushi and Maurer, Matthew and Clausen, Michael Roost and Dessau-Arp, Andriette and Jørgensen, Jennifer Bøgh and Jørgensen, Judit and Larsen, Thomas Stauffer and Pedersen, Lars Møller and Jakobsen, Lasse Hjort and El-Galaly, Tarec Christoffer},
  title = {Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14373}
}
Kostenlos starten →